Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

Abstract: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM. We describe...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Bridget Kim, Jack E. Malespini, Matthew Lei, Samuel S. Han, Cole W. Minsky, Andrew R. Branagan, Elizabeth K. O’Donnell, Diana Cirstea, Noopur S. Raje, Andrew J. Yee
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925001594
Tags: Add Tag
No Tags, Be the first to tag this record!